Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04103749 · ClinicalTrials.gov registry record · NA
Global Prospective Case Series Using a Single-Use Duodenoscope
A NA study of Endoscopic Retrograde Cholangiopancreatography, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 551
- Enrollment target
- 20
- Study locations
NCT04103749: Completed NA study of Endoscopic Retrograde Cholangiopancreatography, sponsored by Boston Scientific Corporation.
NCT04103749 is a NA study of Endoscopic Retrograde Cholangiopancreatography that has completed, run by Boston Scientific Corporation. The registered enrollment target is 551 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04103749, a NA study of Endoscopic Retrograde Cholangiopancreatography, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 551 participants
- Enrollment target
- 20
- Study locations
Study Summary
Confirm procedural performance of the ExaltTM Model D Single-Use Duodenoscope in Endoscopic Retrograde Cholangio-Pancreatography (ERCP) and other duodenoscope-based procedures
Primary Outcome
The ability to complete the ERCP procedure for the intended indication(s); outcome reported as "success" or "failure". Examples include but are not limited to: biliary stent placement, pancreatic stent placement, sphincterotomy, and clearance of bile duct stones.
Conditions Studied
Interventions
- DEVICE Exalt Model D Single-Use Duodenoscope
Study Locations (20)
Other
- Metro North Hospital and Health Services - Brisbane
- St. Michael's Hospital - Unity Health - Toronto
- Institut Paoli-Calmettes - Marseille
- Prince of Wales Hospital - Hong Kong
- Humanitas University - Milan
- Erasmus University Medical Center of Rotterdam - Rotterdam
New York
- North Shore University Hospital - Manhasset
- Cornell Medical Center - New York
California
- University of California Los Angeles Medical Center - Los Angeles
Illinois
- University of Chicago - Chicago
Indiana
- Indianapolis University Hospital - Indianapolis
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2023-01-05 |
| Phase | NA |
What the finished NCT04103749 record still lists
NCT04103749 is an interventional study that assigns participants to a tested intervention. The registered 551 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Endoscopic Retrograde Cholangiopancreatography appearing as the primary indexed condition, and to 1 intervention - of which Exalt Model D Single-Use Duodenoscope is the first listed.
NCT04103749 names 20 study sites across 14 states, led by Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT04103749 about?
NCT04103749 is a clinical study titled "Global Prospective Case Series Using a Single-Use Duodenoscope". Confirm procedural performance of the ExaltTM Model D Single-Use Duodenoscope in Endoscopic Retrograde Cholangio-Pancreatography (ERCP) and other duodenoscope-based procedures
What is the current status of trial NCT04103749?
This trial is currently completed. It is a NA study. The enrollment target is 551 participants. The study started on 2021-03-22. Estimated completion is 2023-01-05.
What conditions does trial NCT04103749 study?
This clinical trial studies the following conditions: Endoscopic Retrograde Cholangiopancreatography.
What interventions are being tested in trial NCT04103749?
The interventions under investigation include: Exalt Model D Single-Use Duodenoscope (DEVICE).
Who is sponsoring clinical trial NCT04103749?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04103749 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endoscopic Retrograde Cholangiopancreatography
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04103749's enrollment target sits among peer trials
551 184th of 2000 higher than 1,817 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI